Company research
BRAINSTORM CELL THERAPEUTICS INC.
CIK 1137883Updated Sep 24, 2026
SecurityBCLI · OTC · equity
Name history
BRAINSTORM CELL THERAPEUTICS INC · through Jul 23, 2012GOLDEN HAND RESOURCES INC · through Nov 22, 2004WIZBANG TECHNOLOGIES INC · through Aug 8, 2003
BCLI price & chart
Loading TradingView…
OTC:BCLI on TradingView ↗About the company
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a leading developer of autologous adult stem cell therapies for debilitating neurodegenerative diseases. The company’s proprietary NurOwn® platform uses autologous mesenchymal stem cells (MSCs) to produce neurotrophic factor-secreting cells (MSC-NTF cells), designed to deliver targeted biological signals that modulate neuroinflammation and promote neuroprotection.
In the news
BrainStorm Cell Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update News provided by BrainStorm Cell Therapeutics Inc. Nov 14, 2025, 16:30 ET Share this article Share to X Share this article Share to X NEW YORK , Nov. 14, 2025 /PRNewswire/ -- BrainStorm Cell The ↗
Seeking Alpha
BrainStorm Cell Therapeutics GAAP EPS of -$0.35 ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
EFFECT filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,022,000Source | 1,832,000Source | 4,208,000Source | 8,451,000Source |
| Property, Plant and Equipment, NetUSD | 235,000Source | 434,000Source | 686,000Source | 933,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 29,000Source | 187,000Source | 1,300,000Source | 772,000Source |
| Assets, CurrentUSD | 307,000Source | 385,000Source | 1,899,000Source | 3,106,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 192,000Source | 135,000Source | 548,000Source | 32,000Source |
| Operating Lease, Right-of-Use AssetUSD | 208,000Source | 807,000Source | 1,416,000Source | 4,389,000Source |
| Other Assets, NoncurrentUSD | 25,000Source | 1,447,000Source | 2,309,000Source | 5,345,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 11,007,000Source | 9,596,000Source | 9,066,000Source | 11,466,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 16,000Source | 14,000Source | 13,000Source | 12,000Source |
| Retained Earnings (Accumulated Deficit)USD | -236,943,000Source | -226,636,000Source | -215,013,000Source | -197,821,000Source |
| Stockholders' Equity Attributable to ParentUSD | -9,985,000Source | -7,764,000Source | -4,858,000Source | -3,015,000Source |
| Additional Paid in Capital, Common StockUSD | 227,058,000Source | 218,974,000Source | 210,258,000Source | 194,910,000Source |
| Liabilities and EquityUSD | 1,022,000Source | 1,832,000Source | 4,208,000Source | 8,451,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,007,000Source | 8,978,000Source | 7,800,000Source | 8,800,000Source |
| Operating Lease, Liability, CurrentUSD | 208,000Source | 549,000Source | 603,000Source | 1,427,000Source |
| Accounts Payable, CurrentUSD | 7,067,000Source | 6,080,000Source | 4,954,000Source | 6,224,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 171,000Source | 672,000Source | 2,666,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 396,000Source | 619,000Source | 1,240,000Source | 84,000Source |
| Short-term InvestmentsUSD | — | — | — | 2,211,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -10,307,000Source | -11,623,000Source | -17,192,000Source | -24,277,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,520,000Source | 750,000Source | 1,490,000Source | 1,682,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | 2,524,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,975,000Source | -9,093,000Source | -20,458,000Source | -19,320,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | 12,000Source | 2,193,000Source | 998,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 18,000Source | 29,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,880,000Source | 7,967,000Source | 18,978,000Source | 238,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -95,000Source | -1,114,000Source | 713,000Source | -18,084,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 276,000Source | 371,000Source | 1,485,000Source | 772,000Source |
| Additional Financial Items | ||||
| DepreciationUSD | 199,000Source | 240,000Source | 265,000Source | 285,000Source |
| General and Administrative ExpenseUSD | 5,778,000Source | 7,042,000Source | 10,693,000Source | 10,866,000Source |
| Net Income (Loss) Attributable to ParentUSD | -10,307,000Source | -11,623,000Source | -17,192,000Source | -24,277,000Source |
| Proceeds from Issuance of Common StockUSD | 186,000,000Source | 180,000,000Source | 171,000Source | 151,000Source |
| Stock or Unit Option Plan ExpenseUSD | 1,520,000Source | 750,000Source | 1,490,000Source | 1,682,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -9,953,000Source | -11,693,000Source | -21,439,000Source | -24,822,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -10,307,000Source | -11,623,000Source | -17,192,000Source | -24,277,000Source |
| Net Income (Loss) Attributable to ParentUSD | -10,307,000Source | -11,623,000Source | -17,192,000Source | -24,277,000Source |
| Earnings Per Share, BasicUSD per share | -1.11Source | -2.31Source | -0.4Source | -0.66Source |
| Earnings Per Share, DilutedUSD per share | -1.11Source | -2.31Source | -0.4Source | -0.66Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 9,268,976Source | 5,021,798Source | 43,075,938Source | 36,509,060Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 9,268,976Source | 5,021,798Source | 43,075,938Source | 36,509,060Source |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 5,778,000Source | 7,042,000Source | 10,693,000Source | 10,866,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -5,068,000Source | -6,142,000Source | -8,837,000Source | -9,989,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | -533,000Source | — | — | — |
| Research and Development ExpenseUSD | 4,175,000Source | 4,651,000Source | 10,746,000Source | 13,956,000Source |
Offerings
Registration 333-296090
Filing attachments
tm2623188d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623188d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, Aug 14, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update. “We continue to advance and complete the pre…
Read attachment ↗tm2621592d1_ex99-1.htm · 8-K · 2026-07-30
EX-99.1 7 tm2621592d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Appoints Former FDA Associate Commissioner Peter J. Pitts as Executive Chairman Professor Jacob Frenkel Transitions to Senior Advisor Peter J. Pitts to lead NurOwn® into Phase 3b trial; advancing under the first Special Protocol Assessment ever granted for an ALS therapeutic candidate NEW YORK, NY - July 28, 2026 - BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of innovative autologous cellular th…
Read attachment ↗tm2615772d1_ex99-1.htm · 8-K · 2026-05-28
EX-99.1 3 tm2615772d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors Former Senior FDA Official Joins Board as Company Prepares to Initiate Historic Phase 3b ALS Trial Under Special Protocol Assessment NEW YORK, NY - May 28, 2026 - BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of autologous stem cell therapies for neurodegenerative diseases, today announced that Peter …
Read attachment ↗tm2614771d1_ex99-1.htm · 8-K · 2026-05-15
EX-99.1 2 tm2614771d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update NEW YORK, May 15, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the three months ended March 31, 2026, and provided a corporate update. “The team at BrainStorm is focused on completi…
Read attachment ↗tm2610751d1_ex99-1.htm · 8-K · 2026-03-31
EX-99.1 2 tm2610751d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update Strategic $2.0 million post year-end financing and re-rating of BCLI shares underscore market confidence Company highlights durable long-term survival in Expanded Access Program (EAP) cohort supporting Phase 3b patient selection and inclusion criteria NEW YORK, March 31, 2026 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTC…
Read attachment ↗tm267482d1_ex4-1.htm · 8-K · 2026-02-27
EX-4.1 2 tm267482d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT …
Read attachment ↗